132 related articles for article (PubMed ID: 38798466)
1. Targeting LxCxE cleft pocket of retinoblastoma protein in M2 macrophages inhibits ovarian cancer progression.
Tcyganov EN; Kwak T; Yang X; Poli ANR; Hart C; Bhuniya A; Cassel J; Kossenkov A; Auslander N; Lu L; Sharma P; Mendoza MGC; Zhigarev D; Cadungog MG; Jean S; Chatterjee-Paer S; Weiner D; Donthireddy L; Bristow B; Zhang R; Tyurin VA; Tyurina YY; Bayir H; Kagan VE; Salvino JM; Montaner LJ
bioRxiv; 2024 May; ():. PubMed ID: 38798466
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
3. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
5. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
6. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
[TBL] [Abstract][Full Text] [Related]
7. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy.
Schweer D; McAtee A; Neupane K; Richards C; Ueland F; Kolesar J
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565348
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
10. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
11. Single-cell characterization of malignant phenotypes and microenvironment alteration in retinoblastoma.
Wu C; Yang J; Xiao W; Jiang Z; Chen S; Guo D; Zhang P; Liu C; Yang H; Xie Z
Cell Death Dis; 2022 May; 13(5):438. PubMed ID: 35523772
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
Truxova I; Cibula D; Spisek R; Fucikova J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822672
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor-associated macrophages in the tumor microenvironment.
Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
16. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
18. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
[TBL] [Abstract][Full Text] [Related]
19. Blocking siglec-10
Xiao N; Zhu X; Li K; Chen Y; Liu X; Xu B; Lei M; Xu J; Sun HC
Exp Hematol Oncol; 2021 Jun; 10(1):36. PubMed ID: 34112250
[TBL] [Abstract][Full Text] [Related]
20. Depletion of tumor-associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin.
Kawaguchi Y; Ohshio Y; Watanabe A; Shiratori T; Okamoto K; Ueda K; Kataoka Y; Suzuki T; Hanaoka J
Cancer Sci; 2023 Mar; 114(3):750-763. PubMed ID: 36411518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
